The Rocket Innovation Award recognises advances in sustained therapeutic protein delivery to the CNS, including the Myo-P5A® programme in development for Sanfilippo syndrome type IIIA Campus Innovation Park, Geneva, Switzerland, 23 October 2026 / EIN Presswire : Release Therapeutics (“Release Tx” or “the Company”), a privately held Swiss BioMedTech company, today announced that a collaborative research project involving Release Tx, Geneva University Hospitals (HUG) and the Un

The competitive, non-dilutive funding reflects confidence in the scientific and translational potential of the Company’s encapsulated cell technology platform and supports its expansion into a second rare CNS indication. Campus Innovation Park, Geneva, Switzerland, 22 October 2026 / EIN Presswire : Release Therapeutics (“Release Tx” or “the Company”), a privately held Swiss BioMedTech company, today announced that it has been awarded a CHF 500,000 Innovation Project grant fro

The award recognises a personalised cancer immunotherapy vaccine developed by UNIGE and HUG that originated at MaxiVax (now Release Therapeutics) Release Therapeutics (Release Tx) is pleased to announce that our research collaborators at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have been awarded the 2026 Pfizer Research Prize in Oncology for their work on the personalised cancer vaccine MVX-ONCO-1. [i] Established in 1992, the Pfizer Research Pr

Best Poster Awards 2022 – ESMO conference – Our ECT technology as adjuvant to an au tologous cancer vaccine.

Our ECT technology as adjuvant to an autologous cancer vaccine.